System solution for syringes, vials and cartridges - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

 

Optima Pharma has, in the form of the INOVA SV, a well proven machine that had been re-engineered in recent years into a highly flexible modular system.

The INOVA SV allows the processing of nested ready to use syringes, of nested vials and cartridges in one unit. Customers make a quick change within 30 minutes. The contact points of the system to the containers are reduced to an absolute minimum to allow for gentler processing. In addition, there is no glass to glass contact of any kind during the processing. A further factor concerns the filling systems. A number of variations are possible, all of which can be set up very quickly as part of the format change work: Rotary piston pumps, peristaltic pumps, mass flow metering and time-pressure systems offer advantages relative to the various types of pharmaceuticals. Additional modules and functions can be integrated, including filling under vacuum, pre- and post-flushing with gas, and up to 100% in-process control. Upstream, the pre-sterilized containers are manually to fully automatically unpacked and fed to the process. The post-processing section features such modules as backstop locks and safety devices, optical and sensor controls, labelers and track & trace systems. RAB systems and isolators can be deployed. A maximum output of 18,000 containers/hour is achieved via ten filling points, with a dosing range of 0.1 to 50 ml.

OPTIMA pharma GmbH
www.optima-pharma.com
E-mail: info@optima-pharma.com

 

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FindPharma Custom Search

Click here